Aduro BioTech Inc. (ADRO) announced Monday morning that its Phase 2b ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer.
from RTT - Before the Bell http://ift.tt/1ThLAo7
via IFTTT
No comments:
Post a Comment